Publication:
Leptin, Both Bad and Good Actor in Cancer.

dc.contributor.authorJiménez-Cortegana, Carlos
dc.contributor.authorLópez-Saavedra, Ana
dc.contributor.authorSánchez-Jiménez, Flora
dc.contributor.authorPérez-Pérez, Antonio
dc.contributor.authorCastiñeiras, Jesús
dc.contributor.authorVirizuela-Echaburu, Juan A
dc.contributor.authorde la Cruz-Merino, Luis de la
dc.contributor.authorSánchez-Margalet, Víctor
dc.date.accessioned2023-02-09T11:41:37Z
dc.date.available2023-02-09T11:41:37Z
dc.date.issued2021-06-20
dc.description.abstractLeptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the "obesity paradox", and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology.
dc.identifier.doi10.3390/biom11060913
dc.identifier.essn2218-273X
dc.identifier.pmcPMC8235379
dc.identifier.pmid34202969
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235379/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2218-273X/11/6/913/pdf
dc.identifier.urihttp://hdl.handle.net/10668/18093
dc.issue.number6
dc.journal.titleBiomolecules
dc.journal.titleabbreviationBiomolecules
dc.language.isoen
dc.organizationHospital Universitario Virgen Macarena
dc.organizationHospital Universitario Virgen Macarena
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcancer
dc.subjectimmune system
dc.subjectimmunotherapy
dc.subjectinflammation
dc.subjectleptin
dc.subjectobesity
dc.subject.meshAdaptive Immunity
dc.subject.meshAnimals
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshLeptin
dc.subject.meshNeoplasm Proteins
dc.subject.meshNeoplasms
dc.subject.meshObesity
dc.titleLeptin, Both Bad and Good Actor in Cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8235379.pdf
Size:
901.02 KB
Format:
Adobe Portable Document Format